Updated:
Jade Biosciences
Jade Biosciences develops therapies for autoimmune diseases within the biotechnology sector. The company creates treatments for patients with these conditions.
Jade Biosciences
Jade Biosciences develops therapies for autoimmune diseases within the biotechnology sector. The company creates treatments for patients with these conditions. Founded in 2024, Jade Biosciences is based in Philadelphia, Pennsylvania.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Philadelphia
Corporate office
Philadelphia, United States
Principals
Tom Frohlich
Chief Executive Officer
Andrew King
President, Research & Development
Edward R. Conner
Chief Medical Officer
Brad Dahms
Chief Financial Officer
Eric Dobmeier
Board Chair and Venture Partner, Samsara Biocapital
Chris Cain
Director of Research, Fairmount
Tomas Kiselak
Founding Partner, Fairmount
Lawrence Klein
Chief Executive Officer, Oruka Therapeutics
Erin Lavelle
Former COO and CFO, ProfoundBio and Eliem Therapeutics
Sector focus
Frequently asked questions
Who controls investment and strategic decisions at Jade Biosciences?
Chief Executive Officer Tom Frohlich leads the company, and the board is chaired by Eric Dobmeier of Samsara Biocapital. Founding partner Tomas Kiselak and Director of Research Chris Cain, both from Fairmount, also serve as directors, indicating significant influence from the parent discovery group. No additional investment committee structures are publicly disclosed.
How does Jade Biosciences source its drug candidates?
Jade does not maintain an internal research lab. The company exclusively in-licenses discovery-stage assets from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. This creates a pipeline without the capital outlay typical of early-stage biologics research.
Is Jade Biosciences structured as a family office or a traditional biotech company?
Jade operates as a clinical-stage biotech company, not a family office. The firm does not publicly disclose any ties to a single-family fortune and is backed by institutional life sciences investors Fairmount and Samsara Biocapital, whose representatives sit on Jade's board.
What is Jade's sole publicly disclosed drug program?
JADE101 is the only named asset. The drug is designed to inhibit the cytokine APRIL and is being developed for immunoglobulin A nephropathy (IgAN). The company does not specify a timeline for clinical data or additional indications in its public materials.
Does Jade Biosciences maintain a philanthropic or foundation arm?
No philanthropic structures or foundations are disclosed in association with Jade Biosciences or its management team.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: